INFOGRAPHIC: Mylan 2Q revenue meets guidance, but forecast narrowed
This article was originally published in Scrip
Executive Summary
Mylan still expects to have a growth year, but in its second quarter earnings report the company lowered the top ends of its 2014 revenue and earnings per share (EPS) guidance by $200m and $0.15, respectively, based on slower-than-expected US FDA approvals for key generic products.